Find information on thousands of medical conditions and prescription drugs.

Thymoma

In medicine (oncology), thymoma is a neoplasm of the thymus. It is a rare disease, best known for its enigmatic association with the neuromuscular disorder myasthenia gravis. There are benign and malignant forms, which present similarly. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
Candidiasis
Tachycardia
Taeniasis
Talipes equinovarus
TAR syndrome
Tardive dyskinesia
Tarsal tunnel syndrome
Tay syndrome ichthyosis
Tay-Sachs disease
Telangiectasia
Telangiectasia,...
TEN
Teratoma
Teratophobia
Testotoxicosis
Tetanus
Tetraploidy
Thalassemia
Thalassemia major
Thalassemia minor
Thalassophobia
Thanatophobia
Thoracic outlet syndrome
Thrombocytopenia
Thrombocytosis
Thrombotic...
Thymoma
Thyroid cancer
Tick paralysis
Tick-borne encephalitis
Tietz syndrome
Tinnitus
Todd's paralysis
Topophobia
Torticollis
Touraine-Solente-Golé...
Tourette syndrome
Toxic shock syndrome
Toxocariasis
Toxoplasmosis
Tracheoesophageal fistula
Trachoma
Transient...
Transient Global Amnesia
Transposition of great...
Transverse myelitis
Traumatophobia
Treacher Collins syndrome
Tremor hereditary essential
Trichinellosis
Trichinosis
Trichomoniasis
Trichotillomania
Tricuspid atresia
Trigeminal neuralgia
Trigger thumb
Trimethylaminuria
Triplo X Syndrome
Triploidy
Trisomy
Tropical sprue
Tropophobia
Trypanophobia
Tuberculosis
Tuberous Sclerosis
Tularemia
Tungiasis
Turcot syndrome
Turner's syndrome
Typhoid
Typhus
Tyrosinemia
U
V
W
X
Y
Z
Medicines

Signs and symptoms

  • 33%-50% is detected accidentally on routine X-rays of the chest.
  • 33% presents with complaints due to compression of surrounding structures by the expanding tumor:
    • Vena cava superior syndrome (compression of the upper caval vein)
    • Dysphagia (trouble swallowing)
    • Cough, chest pain
  • A final 33% has autoimmune symptoms; thymomas in these are usually benign. The best known is myasthenia gravis, of which 25-50% is associated with a thymoma. Some others are: pure red cell aplasia and Good's syndrome (thymoma with combined immunodeficiency and hypoimmunoglobulinemia G).
    • Rare associations that have been reported are: acute pericarditis, Addison's disease, agranulocytosis, alopecia areata, ulcerative colitis, Cushing's disease, hemolytic anemia, limbic encephalopathy, myocarditis, nephrotic syndrome, panhypopituitarism, pernicious anemia, polymyositis, rheumatoid arthritis, sarcoidosis, scleroderma, sensorimotor radiculopathy, stiff person syndrome, systemic lupus erythematosus and thyroiditis.

Malignant thymomas can metastasize, generally to pleura, kidney, bone, liver or brain.

Diagnosis

When a thymic pass is identified, the diagnosis is achieved with histology (obtaining a tissue sample of the mass). When a thymoma is suspected, a CT/CAT scan is generally performed to estimate the size of the tumor, and can be biopsied with a CT-guided needle. Although there is a risk of pneumomediastinum, mediastinitis and the risk of damaging the heart or large blood vessels.

The tumor is generally located inside the thymus, and can be calcified. Increased vascular enhancement can be indicative of malignancy, as can be pleural deposits.

If the suspicion is real, some blood tests are often performed to gain an appreciation of associated problems or possible spread. These include: full blood count, protein electrophoresis, antibodies to the acetylcholine receptor (indicative of myasthenia), electrolytes, liver enzymes and renal function.

The final diagnosis is made by removing the thymus. Pathological investigation of the specimen will reveal if the tumor was benign or malignant.

Pathophysiology

Thymomas originate from the epithelial cell population in the thymus. Many subtypes are recognised, some of which have a better- or worse-than-general prognosis.

Epidemiology

Men and women are equally affected. The main age for thymomas is 30-40, although cases have been described in every age group.

Treatment

Surgery is the mainstay of treatment. If the tumor was benign and was removed in its entirety, no further therapy is necessary. Malignant tumors may need additional treatment with radiotherapy, or sometimes with chemotherapy (cyclophosphamide, doxorubicin and cisplatin).

Read more at Wikipedia.org


[List your site here Free!]


Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone
From CHEST, 10/1/05 by Kohei Yokoi

PURPOSE: Advanced thymomas (stage III with great vessel involvement and Stage IV) are not usually manageable by surgical resection and radiotherapy, and effectiveness of multimodality therapy including chemotherapy has been recently reported. However, the optimal treatment strategy has not been determined. We reviewed our experience with a multidisciplinary approach and evaluated the chemotherapy in the treatment of invasive thymoma.

METHODS: Seventeen patients were treated with multimodality therapy consisted of chemotherapy, surgery, and/or radiotherapy. Four patients had stage III disease with superior vena cava invasion, 9 had stage IVa disease, and 4 had stage IVb disease. The chemotherapy regimen consisted of cisplatin (20 mg/m2/day on days 1-4), doxorubicin (40 mg/m2 on day 1), and methylprednisolone (1,000 mg/day on days 1-4 and 500 mg/day on days 5, 6) (CAMP). Chemotherapy was administered in a neoadjuvant setting to the 14 patients and in an adjuvant setting to the remaining 3patients with stage IVa disease. Surgical resection was intended in all patients. After those treatments, chemotherapy and/or radiation therapy were performed.

RESULTS: All but one of the 14 patients with induction chemotherapy had responded to the CAMP therapy, and the response rate (CR: 1, PR: 13) was 92.8%. One patient with MG, PRCA, and hypogammaglobulinemia died during the chemotherapy. Eight patients of them had a CR after surgical resection and chemoradiotherapy. All three patients treated with surgical resection followed by chemotherapy with or without radiotherapy achieved also a CR. Recurrences occurred in 6 patients, but 4 of them are now alive after re-treatment. The 10-year survival of all the patients was 80.7%, and 11 patients with a complete remission after the multidisciplinary treatment are all alive 9 to 193 months after initiation of the therapy.

CONCLUSION: The CAMP therapy was highly effective to invasive thymomas. The multidisciplinary treatment containing this chemotherapy is considered a justifiable treatment strategy for patients with advanced thymoma.

CLINICAL IMPLICATIONS: The high efficacy of chemotherapy will contribute to improve the outcomes of patients with unresectable invasive thymoma.

DISCLOSURE: Kohei Yokoi, None.

Kohei Yokoi MD * Haruhisa Matsuguma MD Rie Nakahara MD Tetsuro Kondo MD Yukari Kamiyama MD Kiyoshi Mori MD Nagoya Graduate School of Medicine, Nagoya, Japan

COPYRIGHT 2005 American College of Chest Physicians
COPYRIGHT 2005 Gale Group

Return to Thymoma
Home Contact Resources Exchange Links ebay